Embecta beats Q2 with $277M revenue (+4% CC); raises FY2023 adj EPS guidance to $2.50-$2.60

Embecta Corp.

2023-Q2 EPS reported $0.85 revenue$552,800,000

Q2 revenue $277.1M, +4.0% constant currency; US +3.6%, international +4.4% constant currency.
Adjusted EPS $0.75, adjusted operating margin 30.6%, adjusted EBITDA margin 34.9%.
FY2023 guidance raised: revenue $1,101-1,113M (prev $1,084-1,107M), constant currency growth 0-1%.
Adjusted EPS guidance raised to $2.50-2.60 from $2.20-2.35; adj gross margin ~64.5%, adj op margin ~28%.
Declared $0.15/share quarterly dividend; advancing insulin patch pump via Tidepool collaboration for type 2 closed-loop.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Embecta Corp. reported second quarter fiscal 2023 results: revenue $277.1 million, net income $14.0 million, EPS $0.24. Guidance raised.

Period: second quarter fiscal 2023
Revenue: $277.1 million
Net income: $14.0 million
EPS: $0.24
Guidance: raised
Result: reported results

Exact text from the filing

for the three and six-month periods ended March 31, 2023 and March 31, 2022 are not meaningfully comparable. Second Quarter Fiscal Year 2023 Financial Highlights : • Revenues of $277.1 million, up 0.9% on a reported basis; up 4.0% on a constant currency basis ◦ U.S. revenues increased 3.6% on both a reported and constant currency basis ◦ International revenues

View on SEC.gov

Browse all earnings releases →

Embecta Corp. filing history →

Source: SEC EDGAR

accession 0001872789-23-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.